Skip to main content
Figure 3 | BMC Pharmacology

Figure 3

From: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779

Figure 3

Kidney cystadenoma scores according to treatment cohort and lesion subtype (cystic, papillary, solid). Cystadenoma score for each subtype is based on number and size of each lesion as described in methods. a) Average scores are plotted according to treatment cohort in graphical format. b) Average total score per kidney and average score per kidney for each lesion subtype by cohort in table format. "Both" refers to a combination of CCI-779 and IFN-γ.

Back to article page

BMC Pharmacology

ISSN: 1471-2210